Literature review · Metabolism & weight

Tirzepatide

Controlled human trials support weight outcomes for defined clinical tirzepatide preparations. These findings do not authenticate or validate a research-catalogue formulation.

By HeartPep · Reviewed · 8 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The selected evidence includes a large placebo-controlled obesity trial and a later comparison with semaglutide. The selected evidence also includes a randomized adolescent trial and an active-comparator study in early type 2 diabetes.

Identity & scope

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Clinical drug research and a supplier's use of the same name are separate kinds of evidence.

Catalogue labels covered: Tirzepatide.

What the research shows

  • SURMOUNT-1 found greater weight reduction than placebo in adults with obesity without diabetes [1].
  • SURMOUNT-5 directly compared two clinical medicines rather than relying on comparisons between unrelated study populations [2].
  • SURPASS-EARLY adds a two-year comparison with intensified conventional care in adults with early type 2 diabetes [4].
  • The phase 3 adolescent trial reported greater BMI reduction than placebo, alongside more gastrointestinal adverse events [5].

Critical interpretation

Initiation, direct comparison and maintenance answer different questions

SURMOUNT-1 asks about starting treatment relative to placebo; SURMOUNT-5 compares two active medicines; SURMOUNT-4 asks what happens after an initial response and continued exposure. Pooling their headline percentages without the relevant baseline obscures those differences. In SURMOUNT-4, the reported increase after switching to placebo starts from the lower weight reached at randomization, not from the original pretreatment weight. The participants selected for that randomized period also differ from everyone who first entered the lead-in. Such distinctions are central to interpreting durability. [1] [2] [3]

A strong trial result still has a defined scope

Randomization supports causal interpretation within the comparison studied; it does not erase selection criteria, treatment discontinuation or formulation differences. The maintenance trial provides stronger withdrawal evidence than an uncontrolled follow-up, but participants had already completed an active-treatment period, so it cannot fully represent early tolerability among new users. Manufacturer-supported development trials also benefit from independent replication and complete safety appraisal. These findings support research on clinical tirzepatide preparations while leaving the identity, exposure and quality of any separately supplied catalogue material to be established on its own evidence. [3] [1]

The registry and journal report describe one trial

The newly posted registry tables for NCT05433584 report the two-year HbA1c comparison from the same study already published in May. The registry’s mixed-model estimate differs from the treatment-regimen estimate in the journal abstract. The two numbers belong to their respective analyses and must not be combined as independent results. The registry lists four-year outcomes without numerical results in this posting. [4]

Adolescent outcomes require their own assessment

The adolescent trial extends the placebo-controlled evidence beyond adult groups. Serious-event estimates were imprecise, and the study gives limited information about participants with overweight or early stages of puberty. Its BMI effect cannot be used to rank treatments against the differently designed adolescent semaglutide registry trial. [5]

Check the corrected animal study legend

The publisher corrected a discrepancy between a figure legend and the methods for a doxorubicin injury model. The correction is relevant to interpreting the animal experiment. The human data above address different questions. [6]

Limitations & uncertainties

  • The trials do not test the identity, stability, exposure, sterility or clinical effectiveness of HeartPep catalogue products.
  • Their selected populations, follow-up periods and adverse-event patterns limit generalization. These summaries are not treatment or administration instructions.

Open research questions

  • How durable are outcomes after withdrawal, and which outcomes depend on ongoing treatment?
  • How should rare adverse events and population-specific effects be assessed beyond individual trials?

Selected papers & source records

Download bibliography
Human studyNamed compoundAbstract / record checked

1. Tirzepatide Once Weekly for the Treatment of Obesity (opens in a new tab)

Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators (2022). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038 (opens in a new tab) · PMID 35658024

Design & population
72-week double-blind randomized placebo-controlled trial in 2,539 adults without diabetes.
What the study found
Mean weight changes ranged from -15.0% to -20.9% across trial groups, compared with -3.1% with placebo. Gastrointestinal adverse events and discontinuations were reported.
Limits on interpretation
Manufacturer-supported trial of a defined clinical preparation. It does not establish outcomes with other routes or commercial research products.
Human studyNamed compoundAbstract / record checked

2. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (opens in a new tab)

Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators (2025). New England Journal of Medicine. DOI: 10.1056/NEJMoa2416394 (opens in a new tab) · PMID 40353578

Design & population
72-week open-label randomized comparison in 751 adults with obesity without diabetes.
What the study found
Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide; gastrointestinal events were common.
Limits on interpretation
Open-label, manufacturer-funded comparison of defined clinical preparations, without a placebo arm. It did not test commercial research-catalogue products.
Human studyNamed compoundAbstract / record checked

3. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (opens in a new tab)

Aronne LJ, Sattar N, Horn DB, et al.; SURMOUNT-4 Investigators (2024). JAMA. DOI: 10.1001/jama.2023.24945 (opens in a new tab) · PMID 38078870

Design & population
After a 36-week open-label lead-in, 670 participants were randomized to continue tirzepatide or switch to placebo for 52 weeks.
What the study found
From randomization, average weight changed by -5.5% with continued treatment and +14.0% after switching to placebo. Gastrointestinal events remained relevant.
Limits on interpretation
Randomization occurred after the lead-in, selecting participants who completed that phase. This maintenance estimate is not an initiation effect in an untreated population.
Human studyNamed compoundAbstract / record checked

4. Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes: A Randomized Clinical Trial (opens in a new tab)

Del Prato S, Heine RJ, Pérez Manghi FC, et al. (2026). Annals of Internal Medicine. DOI: 10.7326/ANNALS-25-05602 (opens in a new tab) · PMID 42184419

Design & population
Open-label randomized phase 4 SURPASS-EARLY trial in 794 adults with early type 2 diabetes and inadequate glycaemic control on metformin. Published online 26 May 2026. Results for the same trial were first posted in ClinicalTrials.gov on 12 November 2026.
What the study found
At two years the journal abstract reports a treatment-regimen difference in HbA1c of −0.68 percentage points (95% CI −0.84 to −0.51). Gastrointestinal events were the most common adverse events in both groups.
Limits on interpretation
Sponsor-funded and open-label. The comparator was clinician-selected care that could include a GLP-1 receptor agonist. The publisher full text was inaccessible; PubMed abstract and registry tables were consulted.
Human studyNamed compoundFull text consulted

5. Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial (opens in a new tab)

Kelly AS, Pamidipati KC, Rachmiel M, et al. (2026). JAMA. DOI: 10.1001/jama.2026.23420 (opens in a new tab) · PMID 43035096

Design & population
Double-blind phase 3 SURMOUNT-ADOLESCENTS study (NCT06075667). Randomized 160 adolescents to subcutaneous tirzepatide or placebo alongside lifestyle intervention for 72 weeks. Published 15 November 2026.
What the study found
Mean BMI fell by 18.5% versus a 0.5% increase with placebo in the treatment-regimen analysis. Gastrointestinal events occurred in 81.5% versus 54.9%, and 9.3% versus 0% discontinued treatment because of an adverse event.
Limits on interpretation
Sponsor-funded. Most participants had obesity, many had reached sexual maturity, and longer follow-up is needed to assess growth and uncommon harms.
Technical referenceNamed compoundFull text consulted

6. Erratum: Tirzepatide attenuates doxorubicin-induced cardiotoxicity via mitochondrial function improvement (opens in a new tab)

Editorial Office (2026). Translational Cancer Research. DOI: 10.21037/tcr-20262-11 (opens in a new tab) · PMID 42997917

Design & population
Publisher erratum dated 20 October 2026 and indexed by PubMed on 8 November. It applies to mouse study PMID 42180982.
What the study found
The notice corrects the units and distinguishes the four-week treatment period from the later observation period in the figure legend.
Limits on interpretation
Full publisher notice consulted. A correction to an animal experiment does not add a clinical efficacy result.
Human studyNamed compoundAbstract / record checked

7. Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation (opens in a new tab)

Aubrac G et al. (2026). Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.71550 (opens in a new tab) · PMID 43010688

Design & population
Claims-based observational comparison of adults with overweight or obesity and atherosclerotic cardiovascular disease, without diabetes.
What the study found
The adjusted primary comparison did not detect a statistically significant difference in major adverse cardiovascular events between the two groups.
Limits on interpretation
This is not a randomized or equivalence trial. Residual confounding is possible, and the study does not establish interchangeability or the performance of a catalogue product.
Human studyNamed compoundAbstract / record checked

8. Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes (opens in a new tab)

Doma M et al. (2026). American Heart Journal Plus: Cardiology Research and Practice. DOI: 10.1016/j.ahjo.2026.101003 (opens in a new tab) · PMID 43022342

Design & population
Propensity-matched retrospective TriNetX cohort of people with atherosclerotic cardiovascular disease and without diabetes.
What the study found
The analysis did not detect a statistically significant difference between the groups for the reported cardiovascular composite outcomes.
Limits on interpretation
Matching does not exclude residual confounding, and a null difference does not establish equivalence. Cohort overlap with other US database studies was not assessed. This is not evidence about any catalogue product.

Search & review scope

Targeted PubMed and ClinicalTrials.gov results check with DOI and trial registration deduplication. Also checked newly indexed or previously omitted original abstracts and identifiers.. Checked 20 November 2026.

Compared the registry’s two-year primary outcome and four-year fields with the linked journal abstract. Reviewed the JAMA full-text primary results, safety table and study limitations for SURMOUNT-ADOLESCENTS. Read the full publisher erratum for the separate mouse paper. Added selected human study records dated 2026, with study-specific limitations.

The journal abstract and sponsor-submitted registry tables use differently presented analyses. The journal full text was inaccessible during this review. The adolescent JAMA report was available in full. Long-term adolescent safety and comparisons across distinct trials remain uncertain.

Recorded search terms
  • PubMed: tirzepatide, 6–16 November 2026 entry or publication dates
  • ClinicalTrials.gov NCT05433584 results
  • PMID 42184419 / DOI 10.7326/ANNALS-25-05602
  • PMID 43035096 / DOI 10.1001/jama.2026.23420
  • PMID 42997917 / DOI 10.21037/tcr-20262-11
  • PMID 43010688 / DOI 10.1111/dom.71550
  • PMID 43022342 / DOI 10.1016/j.ahjo.2026.101003

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. Tirzepatide: literature review. HeartPep literature library. Reviewed 20 November 2026. https://heartpep.com/us/research/library/tirzepatide.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes